The other indication of ivosidenib is for the treatment of locally advanced or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation based on data from the phase III study AG120‐C‐005 (ClarIDHy). Here, IDH1 is linked to cholangiocarcinoma.